Biology and therapy of immunoglobulin deposition diseases (Q41396701)

30 September 2017

1 reference

title

Biology and therapy of immunoglobulin deposition diseases (English)

1 reference

30 September 2017

2

1 reference

30 September 2017

M V Dhodapkar

1

1 reference

PubMed ID

9081206

30 September 2017

A Solomon

series ordinal

3

1 reference

30 September 2017

1 February 1997

1 reference

Hematology / Oncology Clinics of North America

30 September 2017

1 reference

30 September 2017

11

1 reference

30 September 2017

1

1 reference

30 September 2017

89-110

1 reference

Production and immunodiagnostic applications of antihuman light chain monoclonal antibodies

30 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Fibrillary glomerulonephritis and immunotactoid glomerulopathy: two entities, not one

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Cardiac and pleuropulmonary AL amyloid imaging with technetium-99m labelled aprotinin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Brief report: heavy-chain deposition disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Relevance of class, molecular weight and isoelectric point in predicting human light chain amyloidogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Magnetic Resonance Imaging in Primary Amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Aberrant immunoglobulin synthesis in light chain amyloidosis. Free light chain and light chain fragment production by human bone marrow cells in short-term tissue culture

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Monoclonal immunoglobulin deposition disease: light chain and light and heavy chain deposition diseases and their relation to light chain amyloidosis. Clinical features, immunopathology, and molecular analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

beta-Cyclodextrin interacts with the Alzheimer amyloid beta-A4 peptide

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

AEF: An enigma wrapped in a mystery

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Echocardiographic findings in systemic amyloidosis: spectrum of cardiac involvement and relation to survival.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Overrepresentation of the V kappa IV subgroup in light chain deposition disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Immunoglobulin heavy-chain-associated amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Sensitivity and specificity of the echocardiographic features of cardiac amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Structural characterization of κ II Inc, a new amyloid immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Morphologic and clinical features of fibrillary glomerulonephritis versus immunotactoid glomerulopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Organization of the human immunoglobulin lambda light-chain locus on chromosome 22q11.2.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Light-chain deposition disease: its relation with AL-type amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Primary systemic amyloidosis--a diagnostic primer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Phase II trial of recombinant interferon alfa-2 in the treatment of primary systemic amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Beta 2-microglobulin predicts survival in primary systemic amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Dialysis support of patients with primary systemic amyloidosis. A study of 211 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Specific localization and imaging of amyloid deposits in vivo using 123I-labeled serum amyloid P component

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Long-Term Follow-Up and Response to Chemotherapy in Patients With Light-Chain Deposition Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Specificity of abnormal assembly in immunoglobulin light chain deposition disease and amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Immunoglobulin heavy chain and binding protein complexes are dissociated in vivo by light chain addition

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Ultrastructural immunolabeling: a unique diagnostic tool in monoclonal light chain-related renal diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Growth factors in monoclonal light-chain--related renal diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

A role for destabilizing amino acid replacements in light-chain amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Amyloid fibril formation requires a chemically discriminating nucleation event: studies of an amyloidogenic sequence from the bacterial protein OsmB

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Systemic kappa light chain deposition and amyloidosis in multiple myeloma: novel morphological observations

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Complete amino acid sequence determinations demonstrate identity of the urinary Bence Jones protein (BJP-DIA) and the amyloid fibril protein (AL-DIA) in a case of AL-amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Serial Doppler echocardiographic follow-up of left ventricular diastolic function in cardiac amyloidosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Expressed human immunoglobulin kappa genes and their hypermutation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

The fibrillary glomerulopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Primary systemic amyloidosis: resolution of the nephrotic syndrome with melphalan and prednisone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Intensive therapy in AL amyloidosis and light-chain deposition disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Pulmonary Hemorrhage in a Patient with Fibrillary Glomerulonephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Pathogenic potential of human monoclonal immunoglobulin light chains: relationship of in vitro aggregation to in vivo organ deposition

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Isolation and characterization of the integral glycosaminoglycan constituents of human amyloid A and monoclonal light-chain amyloid fibrils.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Preferential expression of human lambda-light-chain variable-region subgroups in multiple myeloma, AL amyloidosis, and Waldenström's macroglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Diagnosis and treatment of primary amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Renal transplantation in 45 patients with amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Monoclonal immunoglobulin deposition disease (Randall type). Relationship with structural abnormalities of immunoglobulin chains

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Manifestations of systemic light chain deposition

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Pathobiology of cast nephropathy from human Bence Jones proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Differential nephrotoxicity of low molecular weight proteins including Bence Jones proteins in the perfused rat nephron in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Protein and host factors implicated in the pathogenesis of light chain amyloidosis (AL amyloidosis)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Bence Jones proteins and light chains of immunoglobulins. Preferential association of the V lambda VI subgroup of human light chains with amyloidosis AL (lambda).

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Nephrotoxic potential of Bence Jones proteins.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Primary amyloidosis associated with a novel heavy-chain fragment (AH amyloidosis)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Purification of amyloid-associated heparan sulphate proteoglycans and galactosaminoglycan free chains from human tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

A molecular model for self-assembly of amyloid fibrils: immunoglobulin light chains.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Bence Jones proteins: a powerful tool for the fundamental study of protein chemistry and pathophysiology

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Light chain deposition disease of the kidney. Morphological aspects in 24 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Arrest of beta-amyloid fibril formation by a pentapeptide ligand

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Rifampicin prevents the aggregation and neurotoxicity of amyloid beta protein in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Clinical remission after syngeneic bone marrow transplantation in a patient with AL amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

Recombinant immunoglobulin variable domains generated from synthetic genes provide a system for in vitro characterization of light-chain amyloid proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970417-2

7 January 2021

10.1016/S0889-8588(05)70417-2

Identifiers

DOI

1 reference

30 September 2017

1 reference

PubMed ID

9081206